Solel Partners LP Has $63.94 Million Stock Position in CVS Health Co. (NYSE:CVS)

Solel Partners LP lifted its holdings in CVS Health Co. (NYSE:CVS - Free Report) by 26.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,424,400 shares of the pharmacy operator's stock after purchasing an additional 295,500 shares during the quarter. CVS Health comprises 12.5% of Solel Partners LP's holdings, making the stock its 2nd biggest position. Solel Partners LP owned approximately 0.11% of CVS Health worth $63,941,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in CVS. Ridgewood Investments LLC lifted its holdings in shares of CVS Health by 255.7% in the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock valued at $28,000 after purchasing an additional 450 shares in the last quarter. Stonebridge Financial Group LLC acquired a new stake in shares of CVS Health in the fourth quarter valued at approximately $28,000. Hopwood Financial Services Inc. bought a new stake in shares of CVS Health in the fourth quarter worth $29,000. Financial Perspectives Inc grew its position in CVS Health by 137.5% in the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock valued at $36,000 after purchasing an additional 466 shares in the last quarter. Finally, Compass Planning Associates Inc bought a new stake in CVS Health during the 4th quarter worth about $37,000. Institutional investors and hedge funds own 80.66% of the company's stock.

Insiders Place Their Bets

In other CVS Health news, Director Michael F. Mahoney acquired 30,000 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the acquisition, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares of the company's stock, valued at $556,941.90. The trade was a 47.23 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.22% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. UBS Group upped their price target on shares of CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a research report on Friday. Barclays increased their price target on shares of CVS Health from $73.00 to $82.00 and gave the company an "overweight" rating in a report on Friday. Morgan Stanley reaffirmed an "overweight" rating on shares of CVS Health in a research report on Tuesday, April 15th. Edward Jones raised CVS Health from a "hold" rating to a "buy" rating in a report on Thursday, January 30th. Finally, Wells Fargo & Company upped their price target on shares of CVS Health from $68.00 to $73.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, CVS Health has an average rating of "Moderate Buy" and a consensus price target of $74.13.

CVS Health Price Performance

Shares of CVS traded down $0.37 during mid-day trading on Monday, reaching $67.09. The company had a trading volume of 10,650,304 shares, compared to its average volume of 11,505,470. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $72.51. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The company has a market capitalization of $84.59 billion, a price-to-earnings ratio of 18.33, a P/E/G ratio of 0.98 and a beta of 0.57. The company's 50 day simple moving average is $66.72 and its 200 day simple moving average is $58.79.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The business had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The firm's revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.31 EPS. Analysts expect that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. The ex-dividend date was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.96%. CVS Health's dividend payout ratio (DPR) is presently 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.